2.42 USD
+0.07 (+2.98%)
At close: Feb 9, 2026
2.4 USD
-0.02 (-0.83%)
Pre-Market: 2/10/2026, 8:00:06 AM
We assign a fundamental rating of 4 out of 10 to HITI. HITI was compared to 191 industry peers in the Pharmaceuticals industry. While HITI is still in line with the averages on profitability rating, there are concerns on its financial health. HITI is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year HITI has reported negative net income.
- HITI had a positive operating cash flow in the past year.
- In the past 5 years HITI always reported negative net income.
- Of the past 5 years HITI 4 years had a positive operating cash flow.
1.2 Ratios
- HITI has a better Return On Assets (-14.54%) than 62.83% of its industry peers.
- With a Return On Equity value of -57.92%, HITI perfoms like the industry average, outperforming 48.17% of the companies in the same industry.
- The Return On Invested Capital of HITI (5.17%) is better than 82.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.54% | ||
| ROE | -57.92% | ||
| ROIC | 5.17% |
ROA(3y)-11.05%
ROA(5y)-14.75%
ROE(3y)-30.28%
ROE(5y)-32.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HITI's Operating Margin of 2.74% is fine compared to the rest of the industry. HITI outperforms 78.01% of its industry peers.
- In the last couple of years the Operating Margin of HITI has grown nicely.
- The Gross Margin of HITI (25.99%) is comparable to the rest of the industry.
- HITI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.74% | ||
| PM (TTM) | N/A | ||
| GM | 25.99% |
OM growth 3YN/A
OM growth 5Y10.73%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.78%
GM growth 5Y-6.82%
2. Health
2.1 Basic Checks
- HITI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, HITI has more shares outstanding
- The number of shares outstanding for HITI has been increased compared to 5 years ago.
- The debt/assets ratio for HITI is higher compared to a year ago.
2.2 Solvency
- HITI has an Altman-Z score of 1.62. This is a bad value and indicates that HITI is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of 1.62, HITI perfoms like the industry average, outperforming 58.12% of the companies in the same industry.
- The Debt to FCF ratio of HITI is 8.31, which is on the high side as it means it would take HITI, 8.31 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of HITI (8.31) is better than 80.63% of its industry peers.
- A Debt/Equity ratio of 0.94 indicates that HITI is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.94, HITI is not doing good in the industry: 72.77% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 8.31 | ||
| Altman-Z | 1.62 |
ROIC/WACC0.56
WACC9.18%
2.3 Liquidity
- A Current Ratio of 1.37 indicates that HITI should not have too much problems paying its short term obligations.
- The Current ratio of HITI (1.37) is worse than 73.30% of its industry peers.
- A Quick Ratio of 0.70 indicates that HITI may have some problems paying its short term obligations.
- HITI has a Quick ratio of 0.70. This is amonst the worse of the industry: HITI underperforms 85.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
- HITI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -884.13%.
- Looking at the last year, HITI shows a quite strong growth in Revenue. The Revenue has grown by 13.72% in the last year.
- The Revenue has been growing by 48.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-884.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)13.72%
Revenue growth 3Y18.51%
Revenue growth 5Y48.14%
Sales Q2Q%18.61%
3.2 Future
- The Earnings Per Share is expected to grow by 30.45% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 13.96% on average over the next years. This is quite good.
EPS Next Y121.5%
EPS Next 2Y60.32%
EPS Next 3Y46.8%
EPS Next 5Y30.45%
Revenue Next Year29.67%
Revenue Next 2Y19.93%
Revenue Next 3Y18.21%
Revenue Next 5Y13.96%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Based on the Price/Forward Earnings ratio of 24.70, the valuation of HITI can be described as rather expensive.
- Based on the Price/Forward Earnings ratio, HITI is valued a bit cheaper than 75.39% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 27.86, HITI is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.7 |
4.2 Price Multiples
- HITI's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HITI is cheaper than 90.58% of the companies in the same industry.
- 85.34% of the companies in the same industry are more expensive than HITI, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.74 | ||
| EV/EBITDA | 8.6 |
4.3 Compensation for Growth
- HITI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- HITI's earnings are expected to grow with 46.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.32%
EPS Next 3Y46.8%
5. Dividend
5.1 Amount
- HITI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.42
+0.07 (+2.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-29 2026-01-29/amc
Earnings (Next)03-16 2026-03-16
Inst Owners13.66%
Inst Owner Change0.16%
Ins Owners8.85%
Ins Owner ChangeN/A
Market Cap211.15M
Revenue(TTM)593.99M
Net Income(TTM)-50.75M
Analysts80
Price Target5.34 (120.66%)
Short Float %0.35%
Short Ratio0.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.04%
Min Revenue beat(2)0.98%
Max Revenue beat(2)1.09%
Revenue beat(4)3
Avg Revenue beat(4)0.55%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.6%
Revenue beat(8)5
Avg Revenue beat(8)0.13%
Revenue beat(12)9
Avg Revenue beat(12)0.97%
Revenue beat(16)13
Avg Revenue beat(16)7.41%
PT rev (1m)0.11%
PT rev (3m)0.78%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)-50%
EPS NY rev (1m)-1.49%
EPS NY rev (3m)-1.49%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.7 | ||
| P/S | 0.48 | ||
| P/FCF | 21.74 | ||
| P/OCF | 12.04 | ||
| P/B | 3.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.6 |
EPS(TTM)-0.46
EYN/A
EPS(NY)0.1
Fwd EY4.05%
FCF(TTM)0.11
FCFY4.6%
OCF(TTM)0.2
OCFY8.31%
SpS5
BVpS0.74
TBVpS-0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.54% | ||
| ROE | -57.92% | ||
| ROCE | 6.54% | ||
| ROIC | 5.17% | ||
| ROICexc | 6.4% | ||
| ROICexgc | 17.98% | ||
| OM | 2.74% | ||
| PM (TTM) | N/A | ||
| GM | 25.99% | ||
| FCFM | 2.23% |
ROA(3y)-11.05%
ROA(5y)-14.75%
ROE(3y)-30.28%
ROE(5y)-32.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y8.85%
ROICexc growth 3YN/A
ROICexc growth 5Y9.97%
OM growth 3YN/A
OM growth 5Y10.73%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.78%
GM growth 5Y-6.82%
F-Score2
Asset Turnover1.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.94 | ||
| Debt/FCF | 8.31 | ||
| Debt/EBITDA | 2.03 | ||
| Cap/Depr | 43.8% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 2.21 | ||
| Cash Conversion | 58.77% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 1.62 |
F-Score2
WACC9.18%
ROIC/WACC0.56
Cap/Depr(3y)33.59%
Cap/Depr(5y)35.25%
Cap/Sales(3y)1.64%
Cap/Sales(5y)2.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-884.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y121.5%
EPS Next 2Y60.32%
EPS Next 3Y46.8%
EPS Next 5Y30.45%
Revenue 1Y (TTM)13.72%
Revenue growth 3Y18.51%
Revenue growth 5Y48.14%
Sales Q2Q%18.61%
Revenue Next Year29.67%
Revenue Next 2Y19.93%
Revenue Next 3Y18.21%
Revenue Next 5Y13.96%
EBIT growth 1Y6.44%
EBIT growth 3YN/A
EBIT growth 5Y64.03%
EBIT Next Year707.98%
EBIT Next 3Y142.78%
EBIT Next 5Y80.76%
FCF growth 1Y-48.76%
FCF growth 3YN/A
FCF growth 5Y16.8%
OCF growth 1Y-32.86%
OCF growth 3Y74.46%
OCF growth 5Y21.95%
HIGH TIDE INC / HITI FAQ
What is the fundamental rating for HITI stock?
ChartMill assigns a fundamental rating of 4 / 10 to HITI.
What is the valuation status for HITI stock?
ChartMill assigns a valuation rating of 5 / 10 to HIGH TIDE INC (HITI). This can be considered as Fairly Valued.
Can you provide the profitability details for HIGH TIDE INC?
HIGH TIDE INC (HITI) has a profitability rating of 4 / 10.
Can you provide the expected EPS growth for HITI stock?
The Earnings per Share (EPS) of HIGH TIDE INC (HITI) is expected to grow by 121.5% in the next year.